

診療と研究を進化させ 日本の医療を先導する。

世界水準と認められた患者安全推進部のもと、
高度で先進的な医療を安全に提供する名古屋大学医学部附属病院。
革新的な医療開発を目指して
基礎から臨床までをつなぐ研究活動も加速させ、
日本の医療を未来へと先導していきます。

■ 世界水準の患者安全の継続

名古屋大学医学部附属病院は、2019(令和元)年に国立大学病院では初めて国際医療施設評価認証機関(JCI)(※1)の認証を取得し、再受審となる本年3月、更新を果たしました。世界水準の医療の質と患者安全の継続について非常に高い評価を得ることができ、全職員の努力の賜物と考えています。今後もPlan(計画)、Do(実行)、Check(評価)、Action(改善)のサイクルを回し、医療の質と患者安全の向上に努力していきます。

2024年からは医師の働き方改革が始まります。長時間労働が常態化している医師の労働環境を改善することは医師自身の健康を守るだけでなく、医療の質と患者安全を保つ点で地域の皆さんにとっても重要な問題です。医療崩壊を防ぎ、日本の医療を未来へ持続させるためにも当院でも改革を進めます。

■ 高度で先進的な医療の提供

診療面では当院ならではの高度で先進的な医療提供に力を入れています。一つはがんゲノム医療中核拠点病院(※2)としての活動で、多くの患者さんに遺伝子パネル検査をご利用いただいています。検査結果から臓器別ではなくひとつひとつのがんに適した治療薬につなげることができる可能性があり、特に治療薬の開発が困難な希少がんの患者さんにとって一つの希望となっています。ゲノム医療は個々の患者さんの遺伝情報をもとにその患者さんの治療に適した薬剤の検討を可能とするもので、今後はがんだけでなく難病へと適応を広げたいと考えています。さらに、診療に資する情報が少ない希少がんの患者さんに診療科を越えて対応するため、新たに希少がんセンターを設立し、電話相談窓口を設け、地域の患者さんや医師からの相談に応じて情報を提供するほか、適切な診療科や専門医を紹介します。また、内科と外科が緊密に協力しながら高度な技術を要する内視鏡診断をもとに最新の薬物療法を駆使し、必要な場合には適切な手術療法をからだに優しい腹腔鏡下手術で提供する炎症性腸疾患治療センター(IBDセンター)の活動もさらに充実してまいりました。

これらの取り組みの一方で、自治体の要請に応じて、ここまで国立大学



病院長

小寺 泰弘

名古屋大学医学部卒業。医学博士。
名古屋大学大学院医学系研究科消化器外科学教授。
名古屋大学医学部附属病院副病院長を経て、
2019年より現職。

Director of Nagoya University Hospital
Yasuhiro Kodera

Graduated from Nagoya University Medical School. PhD in Medicine. Professor of Gastroenterological Surgery, Nagoya University Graduate School of Medicine. Previously Deputy-director of Nagoya University Medical School and became director in 2019.

病院としては最大級の規模で新型コロナウイルスによる重症患者さんの治療にあたってきました。今後もこうした感染症の脅威に際しては、当院の日常診療をできる限り存続させながら、感染状況に合わせて柔軟に対応していきます。

シームレスな研究体制の構築

臨床での高度な診療を支えるのが、充実した研究活動です。当院は臨床研究中核病院(※3)並びに橋渡し研究支援機関(※4)に指定され、日本の革新的な医療開発を先導する立場にあります。基礎研究の成果をシームレスに臨床応用、実用化に結びつける研究体制が整い、研究者が高いモチベーションをもって研究活動を進める中で、期待の持てる研究シーズも着実に生まれています。先進的な研究成果は治療の一つの選択肢となり得るものです。一例を挙げるなら日本でもトップクラスの診療実績を誇る小児がん治療センターでは、画期的なCAR-T細胞療法の臨床研究が進んでいます。

また、国立大学法人東海国立大学機構(※5)の設立を機に、電子カルテ情報の統合をはじめとする連携が当院と岐阜大学医学部附

属病院との間で進められています。その一環として当院の在宅医療介護連携システム「IIJ電子@連絡帳」(※6)を活用し、愛知県・岐阜県の要介護者の情報から疾患のリスク因子や地域性を解明するなど、予防医療の研究を推進する予定です。地域の皆さんの期待に応えるべく、さらに研究活動を加速させていきます。

- ※1 国際医療施設評価認証機関 (Joint Commission International)
米国の国際的な医療施設評価認証機関。「患者安全」「感染管理」など、さまざまな項目から医療の質と安全を厳しく評価し、世界水準に達した施設に認証が与えられる。
- ※2 がんゲノム医療中核拠点病院
日本のがんゲノム医療を牽引し、がん遺伝子パネル検査や遺伝子情報に基づく適切な治療法の検討、研究や新薬開発、人材育成を担う。現在12の医療機関が指定されている。(2022年5月現在)
- ※3 臨床研究中核病院
国際水準の臨床研究や医師主導治験の中心的な役割を担う病院。医療法に定められた高水準の承認要件をすべて満たすことが求められ、現在14の医療機関が承認されている。(2022年4月現在)
- ※4 橋渡し研究支援機関
大学等の優れた基礎研究の成果を革新的な医薬品・医療機器等として実用化する橋渡し研究を支援するため、一定の要件を満たす機能を有する機関を認定。現在11の医療機関が認定されている。(2022年4月現在)
- ※5 国立大学法人東海国立大学機構
名古屋大学と岐阜大学を一法人のもとに統合。両大学の持てる力を共有し、地域創生への貢献と世界屈指の研究大学への発展を目指す。2020年4月設立。
- ※6 IIJ電子@連絡帳
高齢者の在宅医療介護に関わる行政や各専門職(医師、訪問看護師など)が相互に情報連携するためのICTプラットフォーム。当院が開発、名古屋大学発ベンチャーであるNU-Medライフケアシステムズ株式会社から提供し、株式会社インターネットイニシアティブ(IIJ)が事業化。

Yasuhiro Koderu

We, at the Nagoya University Hospital, are committed to take the lead in medical practice through evolution of novel treatment options generated by our original clinical/translational research.

Nagoya University Hospital provides advanced and cutting-edge medical care safely and ethically in collaboration with the world recognized Department of Patient Safety. The process of innovative medical development through research activities ranging from basic and translational research to clinical trials are accelerated through the assistance of professionals at Department of Advanced Medicine.



■ Ensuring world-class patient safety

Nagoya University Hospital acquired certification from Joint Commission International (JCI) (*1) in 2019 to become the first JCI accredited national university hospital and has subsequently passed another surveillance for renewal in March 2022. Our world-class quality medical care and continued patient safety has been highly commended. I believe this is a well-deserved consequence of hard work by all the hospital staff members. We are determined to continue our efforts to improve the quality of medical care and patient safety through the cycle of Plan, Do, Check, and Action. Nationwide regulations to put into effect the work-style reform for doctors will begin in 2024. Excessive overtime work has been taken for granted as duties of a doctor in Japan. Changing this working environment is an important issue, not only to protect the health of doctors, but ultimately to maintain quality medical care and patient safety. We can hopefully establish a truly sustainable medical care in Japan through promoting the reform, but we will need to overcome a lot of difficulties during the process, especially at the starting phase.

■ Provision of advanced and progressive medical care

In the field of medical treatment, we have focused on providing our original advanced and progressive medical care. One of our activities as a Core Hospital for Cancer Genome Medical Care (*2) has been to provide the Gene Panel Test to many patients. According to the results of this test, we can connect each patient to an optimal treatment drug based on biological characteristics of individual cancer rather than organ-specific clinical trial results. This is particularly beneficial for patients with rare cancers and those in need of late line treatments for refractory cancers, for which conventional scheme of developing a new drug is not always applicable. With genomic medicine, it is possible to consider a suitable drug for the treatment of individual patients based on the genetic information. In the future, we would like to expand its application not only to cancer but also to other intractable diseases. Furthermore, in order to treat patients with rare cancers for which there is little information, the new Rare Cancer Center is established. A telephone consultation service will be set up to provide information and referrals to the appropriate medical department and specialists in response to consultations from patients and physicians in the community. Among the activities of the Inflammatory Bowel Disease Center (IBD Center), the latest drug therapies are carried out based on highly technical endoscopic diagnosis in cooperation with the Department of Internal Medicine and Department of Surgery. Provision of the appropriate surgical treatment as needed has been further enhanced by the use of minimally invasive surgery through endoscopic and robotic approach. In addition to these efforts, in response to the request from the local government, we treat patients with severe COVID-19 symptoms at a scale which is one of the largest for a national university hospital. We will continue to respond flexibly to threats from such infectious diseases while striving to maintain our daily practice, the need for which will continue even during the pandemic phase.

■ Establishment of a seamless research system

Enhanced research activities support advanced clinical treatment. Our hospital has been designated as a Core Clinic Research Hospital (*3) by the Ministry of Health, Labor and Welfare and a Center for Advancing Translational Research (CATR) (*4) by the Ministry of Education, Culture, Sports, Science. Thus, we are expected to be positioned to lead innovative medical developments in Japan. With a research system that seamlessly links the results of basic research to clinical application and practical use in place and researchers who are highly motivated to pursue their research activities, promising research seeds are steadily emerging. The results of advanced research can become an option in the treatment strategy of various diseases. For example, the Children's Cancer Center, esteemed as a top-class facility in Japan, carries out clinical research on revolutionary CAR T cell therapy to treat childhood cancer. In addition, with the establishment of Tokai National Higher Education and Research System (*5), collaboration between our hospital and Gifu University Hospital, including the integration of electronic medical record information, is underway. As a part of this effort, the home medical care coordination system "IJJ Electronics@Contact Book" (*6) will be utilized to promote research in preventive medicine, such as the clarification of disease risk factors and regional characteristics based on information collected from persons requiring care in Aichi and Gifu Prefectures. In response to your expectations, we will seek to even further accelerate our research activities.

*1 Joint Commission International (JCI)

An American global accreditation council of medical organizations that evaluates healthcare quality and safety, including "Patient safety" and "Infection control." Only select facilities that fulfill international standards of care receive JCI accreditation.

*2 Core Hospital for Cancer Genome Medical care

A Core Hospital is a leader in cancer genomic medicine in Japan and is responsible for cancer gene panel testing, examination of appropriate treatments based on genetic information, research and development of new drugs, and human resource development. Twelve medical institutions are currently designated. (As of May 2022)

*3 Core Clinical Research Hospital

Hospital that fulfills a central role in ensuring global standards of clinical research and investigator-initiated trials are upheld. Required to fulfill high standard approval items as specified in the Medical Service Law. Currently, 14 medical facilities have been approved. (As of April 2022)

*4 Center for Advancing Translational Research (CATR)

Certification of institutions which meet certain requirements in order to support translational research for the commercialization of the achievements of outstanding fundamental research at universities and other institutions as innovative pharmaceuticals and medical devices. Currently, 11 medical facilities have been selected. (As of April 2022)

*5 Tokai National Higher Education and Research System (THERS)

Nagoya University and Gifu University were integrated into a single corporation. Both shared their strengths and contribute to regional revitalization aiming for development into a global leader in academic research. Established in April 2020.

*6 IJJ Electronics@Contact Book

This is an ICT platform to coordinate the sharing of information between the government and various medical professionals (doctors, visiting nurses, etc.) involved in home medical care for the elderly. It was developed by our university hospital, provided through NU-Med Life Care Systems, Co. Ltd., a joint venture with Nagoya University and commercialized through Internet Initiative Japan, Inc. (IJJ).